Veracyte Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 48.36.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Veracyte Inc's Score
Industry at a Glance
Industry Ranking
30 / 404
Overall Ranking
102 / 4562
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
48.364
Target Price
+9.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Veracyte Inc Highlights
StrengthsRisks
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 50.32% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 110.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 87.37M shares, decreasing 1.63% quarter-over-quarter.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Ticker SymbolVCYT
CompanyVeracyte Inc
CEOStapley (Marc A)
Websitehttps://www.veracyte.com/
FAQs
What is the current price of Veracyte Inc (VCYT)?
The current price of Veracyte Inc (VCYT) is 42.490.
What is the symbol of Veracyte Inc?
The ticker symbol of Veracyte Inc is VCYT.
What is the 52-week high of Veracyte Inc?
The 52-week high of Veracyte Inc is 50.710.
What is the 52-week low of Veracyte Inc?
The 52-week low of Veracyte Inc is 22.610.
What is the market capitalization of Veracyte Inc?
The market capitalization of Veracyte Inc is 3.36B.
What is the net income of Veracyte Inc?
The net income of Veracyte Inc is 24.14M.
Is Veracyte Inc (VCYT) currently rated as Buy, Hold, or Sell?
According to analysts, Veracyte Inc (VCYT) has an overall rating of Buy, with a price target of 48.364.
What is the Earnings Per Share (EPS TTM) of Veracyte Inc (VCYT)?
The Earnings Per Share (EPS TTM) of Veracyte Inc (VCYT) is 0.387.